Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Impact of medicare part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis
Arthritis Care and Research , 06/09/09
Polinski JM et al. - Most MRDD beneficiaries with RA enrolled in Part D. Although plans assume some costs for biologic DMARDs, the majority of costs are shifted to beneficiaries and to Medicare. Such cost shifting may place these medications out of the beneficiary's financial reach and expose Medicare to high financial liability.
Related Articles
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09
Relevance Score: 70%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 69%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Medicare/Medicaid...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of Medicare Part D on Medicare-Medicaid Dual-Eligible Beneficiaries' Prescription Utilization and Expenditures
Health Services Research, 12/08/09
Identifying Clinically Questionable Psychotropic Prescribing Practices for Medicaid Recipients in New York State
Psychiatric Services, 12/07/09
Joint replacement surgeries among medicare beneficiaries in rural compared with urban areas
Arthritis & Rheumatism, 12/07/09
Article Search
Sponsor


See Latest Articles


